Thymosin Alpha-1

Mechanism of Action

A 28-amino-acid peptide produced naturally by the thymus. It signals through toll-like receptor 9 on dendritic cells, pushing differentiation toward a Th1 response, supporting T-cell maturation and normalising cytokine output. It modulates an immune system rather than simply stimulating one, which is why it has been trialled in both immunosuppression and inflammation.

Typical Protocol

Educational reference only — not medical advice.

Pharmacokinetics & Dosing Rationale

Thymosin Alpha-1 is administered subcutaneous injection with an approximate systemic half-life of Roughly 2 hours. The 25-hour figure widely quoted online is for an engineered Fc-fusion variant used in research, not the peptide sold as Tα1.. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Twice weekly) is designed to match receptor kinetics rather than plasma exposure. A 28-amino-acid peptide produced naturally by the thymus. It signals through toll-like receptor 9 on dendritic cells, pushing differentiation toward a Th1 response, supporting T-cell maturation and normalising cytokine output. It modulates an immune system rather than simply stimulating one, which is why it has been trialled in both immunosuppression and inflammation.

How to Administer

1. Route: Subcutaneous injection. Typical starting dose 1.6 mg, Twice weekly.
2. Timing: Any time of day; consistency matters more than timing — keep it the same each dosing day to make effects legible.
3. Cycle length: 6-12 months in the hepatitis trials. Reassess with bloods and symptom logs before repeating.
4. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Reconstitution & Injection Technique

1. Reconstitute lyophilised powder with bacteriostatic water (0.9% benzyl alcohol) — sterile water is acceptable but shortens shelf life to ~72 hours.
2. Typical dilution: add 2 mL of bacteriostatic water to a 5 mg vial → 2.5 mg/mL; a 10-unit insulin syringe mark = 0.25 mg.
3. Inject the diluent slowly against the vial wall — never onto the powder — and gently swirl. Do not shake; peptides denature under shear.
4. Once reconstituted, store upright in the refrigerator (2–8 °C) and use within 30 days.
5. Draw the dose with an insulin syringe (29–31G, 8 mm), swab the site with alcohol, pinch subcutaneous tissue on the abdomen or thigh, inject at 90°.

Sterile technique is not optional. Use a fresh needle for every injection.

Cycling & Stacking Strategy

• Standard protocol: 1.6 mg, Twice weekly, for 6-12 months in the hepatitis trials.
• Ramp up: start at the lower end of the dose range for the first 7–10 days to gauge tolerance and side effects before titrating.
• Break periods let receptor sensitivity and endogenous feedback loops normalise — running back-to-back cycles without a wash-out erodes the effect.
• Common stack: Vitamin D3 sufficiency, Zinc, Adequate sleep. Introduce one compound at a time so you can attribute effect and side effect.

Who This Is For

What to Monitor

Reported Benefits

• Reduced 28-day mortality in a meta-analysis of sepsis trials (RR 0.77)
• 40.6% versus 9.4% complete virological response in the pivotal hepatitis B trial
• Restores T-cell counts and function in immunosuppressed patients
• Well tolerated across long treatment courses

Safety Profile

Common Mistakes

• Chasing a bigger dose instead of consistency — Thymosin Alpha-1 outcomes track cumulative exposure, not peak concentration.
• Skipping baseline bloods, so there is no way to know whether the cycle actually moved a biomarker.
• Stacking three or four novel compounds at once — you lose the ability to attribute any effect or side effect.
• Ignoring the training, sleep and nutrition fundamentals that are prerequisites for every peptide protocol.
• Reusing insulin needles or failing to rotate injection sites — a preventable cause of local reactions and lipohypertrophy.

Evidence Grade — B

Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Below are the primary references used to grade Thymosin Alpha-1. Follow the links for full-text where available and cross-check against the current literature.

Frequently Asked Questions

References

1. [1]The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — Critical Care, 2013
2. [2]Thymosin alpha-1 for sepsis management: a systematic review and meta-analysis — Open Forum Infectious Diseases, 2025

Further reading: Research library → · Protocols →